Alesta Therapeutics

Alesta Therapeutics is an emerging private biotech company developing oral small molecule drugs for rare diseases, with its lead program, ALE1, targeting Hypophosphatasia (HPP). The company is backed by a €65 million Series A financing round from leading life science investors, announced in January 2025. With a globally experienced team, Alesta emphasizes a patient-centric development model, combining scientific precision with practical advantages like oral delivery and cost-effectiveness. The company is preparing to highlight clinical progress for ALE1 at a major industry conference in early 2026.

Strategic focus on developing oral small molecule drugs, leveraging their advantages in oral delivery, tissue penetration, scalable manufacturing, and precise targeting for chronic, multisystemic rare diseases.

In HPP, Alesta's ALE1 would compete directly with enzyme replacement therapy (asfotase alfa), an injectable treatment. The competitive advantage hinges on demonstrating that an oral small molecule can offer comparable or superior efficacy with greatly improved convenience. More broadly, it competes with other biotechs targeting rare diseases with small molecule approaches.